{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T17:04:37Z","timestamp":1788887077417,"version":"build-2803163510"},"reference-count":82,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,2]]},"DOI":"10.1097\/cad.0000000000000032","type":"journal-article","created":{"date-parts":[[2013,10,10]],"date-time":"2013-10-10T20:28:47Z","timestamp":1381436927000},"page":"225-234","source":"Crossref","is-referenced-by-count":61,"title":["Life-threatening dermatologic adverse events in oncology"],"prefix":"10.1097","volume":"25","author":[{"given":"Alyx C.","family":"Rosen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yevgeniy","family":"Balagula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis W.","family":"Raisch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vishvas","family":"Garg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatrice","family":"Nardone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Larsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Sorrell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis P.","family":"West","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milan J.","family":"Anadkat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario E.","family":"Lacouture","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-12-20210227","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1001\/archderm.138.8.1019","article-title":"Correlations between clinical patterns and causes of erythema multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis: results of an international prospective study.","volume":"138","author":"Auquier-Dunant","year":"2002","journal-title":"Arch Dermatol"},{"key":"R2-12-20210227","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/1523-1747.ep12388434","article-title":"The spectrum of Stevens-Johnson syndrome and toxic epidermal necrolysis: a clinical classification.","volume":"102","author":"Roujeau","year":"1994","journal-title":"J Invest Dermatol"},{"key":"R3-12-20210227","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1001\/archderm.1993.01680220104023","article-title":"Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme.","volume":"129","author":"Bastuji-Garin","year":"1993","journal-title":"Arch Dermatol"},{"key":"R6-12-20210227","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.intimp.2005.11.012","article-title":"Use of intravenous immunoglobulin in toxic epidermal necrolysis and Stevens-Johnson syndrome: our current understanding.","volume":"6","author":"French","year":"2006","journal-title":"Int Immunopharmacol"},{"key":"R7-12-20210227","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/S1085-5629(96)80036-8","article-title":"Epidemiology of drug-induced severe skin reactions.","volume":"15","author":"Mockenhaupt","year":"1996","journal-title":"Semin Cutan Med Surg"},{"key":"R8-12-20210227","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1001\/archderm.1987.01660330071012","article-title":"Toxic epidermal necrolysis. Clinical findings and prognosis factors in 87 patients.","volume":"123","author":"Revuz","year":"1987","journal-title":"Arch Dermatol"},{"key":"R9-12-20210227","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1001\/archderm.1990.01670250043005","article-title":"Toxic epidermal necrolysis (Lyell syndrome). Incidence and drug etiology in France, 1981-1985.","volume":"126","author":"Roujeau","year":"1990","journal-title":"Arch Dermatol"},{"key":"R11-12-20210227","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1016\/S0140-6736(00)02826-9","article-title":"Epidemiological assessment of drug-induced disease.","volume":"356","author":"Kaufman","year":"2000","journal-title":"Lancet"},{"key":"R12-12-20210227","doi-asserted-by":"crossref","first-page":"159","DOI":"10.2165\/00002018-200326030-00003","article-title":"Quantitative methods in pharmacovigilance: focus on signal detection.","volume":"26","author":"Hauben","year":"2003","journal-title":"Drug Saf"},{"key":"R13-12-20210227","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1159\/000229752","article-title":"Risk of high-grade skin rash in cancer patients treated with cetuximab - an antibody against epidermal growth factor receptor: systemic review and meta-analysis.","volume":"77","author":"Su","year":"2009","journal-title":"Oncology"},{"key":"R14-12-20210227","doi-asserted-by":"crossref","first-page":"143","DOI":"10.2165\/00002018-200730020-00004","article-title":"Potential use of data-mining algorithms for the detection of surprise adverse drug reactions.","volume":"30","author":"Hauben","year":"2007","journal-title":"Drug Saf"},{"key":"R17-12-20210227","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1002\/pds.677","article-title":"Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports.","volume":"10","author":"Evans","year":"2001","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"R18-12-20210227","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1016\/S0149-2918(04)90181-6","article-title":"Association of asthma therapy and Churg-Strauss syndrome: an analysis of postmarketing surveillance data.","volume":"26","author":"DuMouchel","year":"2004","journal-title":"Clin Ther"},{"key":"R19-12-20210227","doi-asserted-by":"crossref","first-page":"385","DOI":"10.2165\/00002018-200629050-00003","article-title":"Under-reporting of adverse drug reactions: a systematic review.","volume":"29","author":"Hazell","year":"2006","journal-title":"Drug Saf"},{"key":"R20-12-20210227","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1002\/pds.848","article-title":"Biases affecting the proportional reporting ratio (PPR) in spontaneous reports pharmacovigilance databases: the example of sertindole.","volume":"12","author":"Moore","year":"2003","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"R21-12-20210227","doi-asserted-by":"crossref","first-page":"459","DOI":"10.2165\/00002018-200225060-00011","article-title":"Signal selection and follow-up in pharmacovigilance.","volume":"25","author":"Meyboom","year":"2002","journal-title":"Drug Saf"},{"key":"R22-12-20210227","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1046\/j.1365-2141.2002.37133.x","article-title":"Sti571-induced Stevens-Johnson syndrome.","volume":"119","author":"Vidal","year":"2002","journal-title":"Br J Haematol"},{"key":"R23-12-20210227","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1345\/aph.1E127","article-title":"Adverse reactions during imatinib and lansoprazole treatment in gastrointestinal stromal tumors.","volume":"39","author":"Severino","year":"2005","journal-title":"Ann Pharmacother"},{"key":"R24-12-20210227","doi-asserted-by":"crossref","first-page":"288","DOI":"10.4103\/0378-6323.16628","article-title":"Imatinib induced Stevens-Johnson syndrome: lack of recurrence following re-challenge with a lower dose.","volume":"71","author":"Pavithran","year":"2005","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"R25-12-20210227","doi-asserted-by":"crossref","first-page":"3434","DOI":"10.1182\/blood-2002-08-2431","article-title":"Managing cutaneous reactions to imatinib therapy.","volume":"100","author":"Rule","year":"2002","journal-title":"Blood"},{"key":"R27-12-20210227","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1159\/000218097","article-title":"Stevens-Johnson syndrome induced by combination of imatinib and allopurinol.","volume":"55","author":"Hsieh","year":"2009","journal-title":"Chemotherapy"},{"key":"R28-12-20210227","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1007\/s00277-007-0265-y","article-title":"Imatinib-induced Stevens-Johnson syndrome: recurrence after re-challenge with a lower dose.","volume":"86","author":"Mahapatra","year":"2007","journal-title":"Ann Hematol"},{"key":"R29-12-20210227","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1111\/j.1468-3083.2009.03183.x","article-title":"Docetaxel-induced Stevens-Johnson syndrome with regenerating epidermis composed of atypical keratinocytes.","volume":"23","author":"Sawada","year":"2009","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"R30-12-20210227","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1007\/s00120-007-1367-9","article-title":"Lethal course after chemotherapy with docetaxel. Acute liver failure with accompanying erythema multiforme major.","volume":"46","author":"Ohlmann","year":"2007","journal-title":"Urologe A"},{"key":"R32-12-20210227","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s00404-004-0643-9","article-title":"Erythema multiforme major following docetaxel.","volume":"271","author":"Moisidis","year":"2005","journal-title":"Arch Gynecol Obstet"},{"key":"R33-12-20210227","first-page":"95","article-title":"Stevens-Johnson syndrome associated with methotrexate treatment for non-Hodgkins lymphoma.","volume":"62","author":"Cuthbert","year":"1993","journal-title":"Ulster Med J"},{"key":"R34-12-20210227","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1111\/j.1651-2227.1978.tb16318.x","article-title":"High dose methotrexate in acute lymphocytic leukemia in childhood.","volume":"67","author":"Moe","year":"1978","journal-title":"Acta Paediatr Scand"},{"key":"R35-12-20210227","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1177\/030089168607200316","article-title":"Stevens-Johnson syndrome and fatal pulmonary toxicity to combination chemotherapy containing bleomycin: a case report.","volume":"72","author":"Giaccone","year":"1986","journal-title":"Tumori"},{"key":"R36-12-20210227","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1002\/j.1552-4604.1989.tb03426.x","article-title":"Stevens-Johnson syndrome, respiratory distress and acute renal failure due to synergic bleomycin-cisplatin toxicity.","volume":"29","author":"Brodsky","year":"1989","journal-title":"J Clin Pharmacol"},{"key":"R37-12-20210227","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1200\/JCO.1995.13.4.983","article-title":"Cladribine in the treatment of relapsed or refractory chronic lymphocytic leukemia.","volume":"13","author":"Tallman","year":"1995","journal-title":"J Clin Oncol"},{"key":"R39-12-20210227","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/S0190-9622(97)70341-4","article-title":"Stevens-Johnson syndrome associated with topical nitrogen mustard therapy.","volume":"36","author":"Newman","year":"1997","journal-title":"J Am Acad Dermatol"},{"key":"R41-12-20210227","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1093\/annonc\/mdf350","article-title":"Stevens-Johnson syndrome after treatment with rituximab.","volume":"13","author":"Lowndes","year":"2002","journal-title":"Ann Oncol"},{"key":"R43-12-20210227","doi-asserted-by":"crossref","first-page":"264","DOI":"10.2165\/00128071-200910040-00007","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis overlap due to oral temozolomide and cranial radiotherapy.","volume":"10","author":"Sarma","year":"2009","journal-title":"Am J Clin Dermatol"},{"key":"R44-12-20210227","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.clon.2007.11.005","article-title":"Stevens-Johnson syndrome after treatment with capecitabine.","volume":"20","author":"Sendur","year":"2008","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"R45-12-20210227","first-page":"1050","article-title":"Stevens-Johnson syndrome associated with etoposide therapy.","volume":"67","author":"Jameson","year":"1983","journal-title":"Cancer Treat Rep"},{"key":"R46-12-20210227","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1200\/JCO.2008.20.3737","article-title":"Erythema multiformeStevens-Johnson syndrometoxic epidermal necrolysis in lenalidomide-treated patients.","volume":"27","author":"Castaneda","year":"2009","journal-title":"J Clin Oncol"},{"key":"R47-12-20210227","first-page":"1119","article-title":"The usefulness of TS-1 for the treatment of head and neck cancer.","volume":"30","author":"Okamoto","year":"2003","journal-title":"Gan To Kagaku Ryoho"},{"key":"R48-12-20210227","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1111\/j.1346-8138.2004.tb00603.x","article-title":"Drug eruption due to peplomycin: an unusual form of Stevens-Johnson syndrome with pustules.","volume":"31","author":"Umebayashi","year":"2004","journal-title":"J Dermatol"},{"key":"R49-12-20210227","doi-asserted-by":"crossref","first-page":"87","DOI":"10.2165\/00002018-200124020-00002","article-title":"Thalomid (thalidomide) capsules: a review of the first 18 months of spontaneous postmarketing adverse event surveillance, including off-label prescribing.","volume":"24","author":"Clark","year":"2001","journal-title":"Drug Saf"},{"key":"R51-12-20210227","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s00277-011-1235-y","article-title":"Stevens-Johnsontoxic epidermal necrolysis overlap syndrome following lenalidomide treatment for multiple myeloma relapse after allogeneic transplantation.","volume":"91","author":"Wasch","year":"2012","journal-title":"Ann Hematol"},{"key":"R52-12-20210227","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1111\/j.1365-4632.2011.05356.x","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis overlap in a patient receiving cetuximab and radiotherapy for head and neck cancer.","volume":"51","author":"Urosevic-Maiwald","year":"2012","journal-title":"Int J Dermatol"},{"key":"R53-12-20210227","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1097\/CMR.0b013e3283573437","article-title":"Successful desensitization in a case of Stevens-Johnson syndrome due to vemurafenib.","volume":"22","author":"Minor","year":"2012","journal-title":"Melanoma Res"},{"key":"R54-12-20210227","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1592\/phco.31.9.925","article-title":"Possible lenalidomide-induced Stevens-Johnson syndrome during treatment for multiple myeloma.","volume":"31","author":"Boruah","year":"2011","journal-title":"Pharmacotherapy"},{"key":"R55-12-20210227","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1097\/00001813-199706000-00009","article-title":"Severe adverse skin reaction to chlorambucil in a patient with chronic lymphocytic leukemia.","volume":"8","author":"Aydogdu","year":"1997","journal-title":"Anticancer Drugs"},{"key":"R57-12-20210227","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1097\/00007611-199206000-00020","article-title":"Interleukin-2-induced dermatotoxicity resembling toxic epidermal necrolysis.","volume":"85","author":"Wiener","year":"1992","journal-title":"South Med J"},{"key":"R58-12-20210227","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1046\/j.1525-1470.2001.018001038.x","article-title":"Toxic epidermal necrolysis after the use of high-dose cytosine arabinoside.","volume":"18","author":"Ozkan","year":"2001","journal-title":"Pediatr Dermatol"},{"key":"R59-12-20210227","first-page":"53","article-title":"Toxic epidermal necrolysis after the use of intermediate dose of cytosine arabinoside.","volume":"44","author":"Figueiredo","year":"1998","journal-title":"Rev Assoc Med Bras"},{"key":"R60-12-20210227","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1097\/00001813-200309000-00012","article-title":"Stevens-Johnson syndrometoxic epidermal necrolysis in a patient receiving concurrent radiation and gemcitabine.","volume":"14","author":"Sommers","year":"2003","journal-title":"Anticancer Drugs"},{"key":"R61-12-20210227","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1179\/joc.2003.15.5.510","article-title":"Toxic epidermal necrolysis associated with gemcitabine therapy in a patient with metastatic transitional cell carcinoma of the bladder.","volume":"15","author":"Mermershtain","year":"2003","journal-title":"J Chemother"},{"key":"R62-12-20210227","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1046\/j.1365-4362.2000.00022-3.x","article-title":"Toxic epidermal necrolysis following combination of methotrexate and trimethoprim-sulfamethoxazole.","volume":"39","author":"Yang","year":"2000","journal-title":"Int J Dermatol"},{"key":"R63-12-20210227","first-page":"426","article-title":"Toxic epidermal necrolysis in a girl with leukemia receiving methotrexate.","volume":"38","author":"Cakesen","year":"2001","journal-title":"Indian Pediatr"},{"key":"R64-12-20210227","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1046\/j.1365-2230.1999.00473.x","article-title":"Toxic epidermal necrolysis and graft vs. host disease: a clinical spectrum but a diagnostic dilemma.","volume":"24","author":"Stone","year":"1999","journal-title":"Clin Exp Dermatol"},{"key":"R65-12-20210227","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1056\/NEJM200009283431315","article-title":"Life-threatening toxic epidermal necrolysis with thalidomide therapy for myeloma.","volume":"343","author":"Rajkumar","year":"2000","journal-title":"N Engl J Med"},{"key":"R66-12-20210227","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1592\/phco.19.15.1177.30571","article-title":"Thalidomide-induced toxic epidermal necrolysis.","volume":"19","author":"Horowitz","year":"1999","journal-title":"Pharmacotherapy"},{"key":"R69-12-20210227","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1159\/000102604","article-title":"Severe epidermal necrolysis after bortezomib treatment for multiple myeloma.","volume":"118","author":"Fang","year":"2007","journal-title":"Acta Haematol"},{"key":"R71-12-20210227","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.amjoto.2009.02.021","article-title":"Toxic epidermal necrolysis caused by cetuximab plus minocycline in head and neck cancer.","volume":"31","author":"Lee","year":"2010","journal-title":"Am J Otolaryngol"},{"key":"R72-12-20210227","doi-asserted-by":"crossref","first-page":"385","DOI":"10.2340\/0001555576385386","article-title":"Cutaneous reactions after treatment with 2-chlorodeoxyadenosine.","volume":"76","author":"Meunier","year":"1996","journal-title":"Acta Derm Venereol"},{"key":"R74-12-20210227","doi-asserted-by":"crossref","first-page":"3030","DOI":"10.1200\/JCO.2002.20.13.3030","article-title":"Treatment side effects. Case 2. Toxic, epidermal, necrolysis-like reaction associated with docetaxel chemotherapy.","volume":"20","author":"Dourakis","year":"2002","journal-title":"J Clin Oncol"},{"key":"R75-12-20210227","first-page":"711","article-title":"Doxorubicin-enhanced skin reaction after whole-body electron-beam irradiation for leukemia cutis.","volume":"55","author":"Solberg","year":"1980","journal-title":"Mayo Clin Proc"},{"key":"R76-12-20210227","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s00277-003-0643-z","article-title":"Severe epidermal necrolysis after treatment with imatinib and consecutive allogeneic hematopoietic stem cell transplantation.","volume":"82","author":"Schaich","year":"2003","journal-title":"Ann Hematol"},{"key":"R77-12-20210227","first-page":"355","article-title":"L-Asparaginase and toxic epidermal necrolysis.","volume":"69","author":"Rodriguez","year":"1980","journal-title":"J Med Assoc Ga"},{"key":"R78-12-20210227","first-page":"514","article-title":"Lyells syndrome caused by 6-mercaptopurine.","volume":"44","author":"Amerio","year":"1969","journal-title":"G Ital Dermatol Minerva Dermatol"},{"key":"R79-12-20210227","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.clon.2005.09.002","article-title":"Toxic epidermal necrolysis after PCV combination chemotherapy for relapsed B-cell lymphoma.","volume":"18","author":"Jones","year":"2006","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"R80-12-20210227","first-page":"2775","article-title":"Report of a case of Lyells syndrome during a course of treatment with Natulan.","volume":"64","author":"Garbarini","year":"1973","journal-title":"Minerva Med"},{"key":"R82-12-20210227","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/S0761-8425(07)91133-X","article-title":"Severe cutaneous toxicity after Pemetrexed as second line treatment for a refractory non small cell lung cancer.","volume":"24","author":"Tummino","year":"2007","journal-title":"Rev Mal Respir"},{"key":"R85-12-20210227","first-page":"42","article-title":"Mithramycin as a possible cause of toxic epidermal necrolysis (Lyells syndrome).","volume":"114","author":"Eyster","year":"1971","journal-title":"Calif Med"},{"key":"R86-12-20210227","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1056\/NEJM197812212992510","article-title":"Toxic epidermal necrolysis after mithramycin.","volume":"299","author":"Purpora","year":"1978","journal-title":"N Engl J Med"},{"key":"R88-12-20210227","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/0304-3835(90)90030-2","article-title":"Unusual reaction to chlorambucil: a case report.","volume":"54","author":"Pietrantonio","year":"1990","journal-title":"Cancer Lett"},{"key":"R89-12-20210227","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1093\/jjco\/hyr032","article-title":"Toxic epidermal necrolysis associated with TS-1 in a patient with gastric cancer.","volume":"41","author":"Tan","year":"2011","journal-title":"Jpn J Clin Oncol"},{"key":"R90-12-20210227","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1111\/j.1365-2133.2011.10734.x","article-title":"Sequential Stevens-Johnson syndrome and photo-recall phenomenon.","volume":"166","author":"Lee","year":"2012","journal-title":"Br J Dermatol"},{"key":"R93-12-20210227","doi-asserted-by":"crossref","first-page":"e153","DOI":"10.1016\/j.leukres.2012.03.006","article-title":"Stevens-Johnson syndrome after treatment with bendamustine.","volume":"36","author":"Lambertini","year":"2012","journal-title":"Leuk Res"},{"key":"R94-12-20210227","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1159\/000345109","article-title":"Toxic epidermal necrolysis after pemetrexed and cisplatin for non-small cell lung cancer in a patient with sharp syndrome.","volume":"35","author":"Then","year":"2012","journal-title":"Onkologie"},{"key":"R95-12-20210227","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1159\/000342671","article-title":"Toxic epidermal necrolysis related to cisplatin and pemetrexed for metastatic non-small cell lung cancer.","volume":"35","author":"Scheinpflug","year":"2012","journal-title":"Onkologie"},{"key":"R96-12-20210227","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1080\/07853890701753664","article-title":"Stevens-Johnson syndrome: pathogenesis, diagnosis, and management.","volume":"40","author":"Hazin","year":"2008","journal-title":"Ann Med"},{"key":"R97-12-20210227","doi-asserted-by":"crossref","first-page":"9","DOI":"10.2332\/allergolint.55.9","article-title":"Toxic epidermal necrolysis and Stevens-Johnson syndrome: our current understanding.","volume":"55","author":"French","year":"2006","journal-title":"Allergol Int"},{"key":"R98-12-20210227","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1001\/archderm.1995.01690170041005","article-title":"Erythema multiforme with mucous membrane involvement and Stevens-Johnson syndrome are clinically different disorders with distinct causes.","volume":"131","author":"Assier","year":"1995","journal-title":"Arch Dermatol"},{"key":"R99-12-20210227","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.autrev.2008.06.004","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis.","volume":"7","author":"Borchers","year":"2008","journal-title":"Autoimmun Rev"},{"key":"R100-12-20210227","doi-asserted-by":"crossref","first-page":"917","DOI":"10.2165\/00002018-200528100-00008","article-title":"Comparison of reporting of Stevens-Johnson syndrome and toxic epidermal necrolysis in association with selective COX-2 inhibitors.","volume":"28","author":"La Grenade","year":"2005","journal-title":"Drug Saf"},{"key":"R105-12-20210227","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s11523-011-0174-9","article-title":"Common toxicities of mammalian target of rapamycin inhibitors.","volume":"6","author":"Soefje","year":"2011","journal-title":"Target Oncol"},{"key":"R106-12-20210227","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1002\/pds.962","article-title":"Under-reporting of serious adverse drug reactions in Sweden.","volume":"13","author":"Backstrom","year":"2004","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"R107-12-20210227","doi-asserted-by":"crossref","first-page":"19","DOI":"10.2165\/00002018-200932010-00002","article-title":"Determinants of under-reporting of adverse drug reactions: a systematic review.","volume":"32","author":"Lopez-Gonzalez","year":"2009","journal-title":"Drug Saf"},{"key":"R108-12-20210227","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/j.1365-2133.2011.10623.x","article-title":"Is drug allergy less prevalent than previously assumed A 5-year analysis.","volume":"166","author":"Heinzerling","year":"2012","journal-title":"Br J Dermatol"}],"container-title":["Anti-Cancer Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CAD.0000000000000032","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,5]],"date-time":"2023-07-05T07:08:22Z","timestamp":1688540902000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00001813-201402000-00012"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,2]]},"references-count":82,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.1097\/cad.0000000000000032","relation":{},"ISSN":["0959-4973"],"issn-type":[{"value":"0959-4973","type":"print"}],"subject":[],"published":{"date-parts":[[2014,2]]}}}